Proteomics and Metabolomics Shared Resource Project Summary/Abstract The Proteomics and Metabolomics Shared Resource (PMSR) consists of a Fred Hutchinson Cancer Research Center (FHCRC)-based Proteomics/Metabolomics laboratory and a University of Washington-South Lake Union (UW-SLU) laboratory. The Proteomics section of the PMSR was formed in November 2002 with the goal of providing cost-effective high performance liquid chromatography and mass spectrometry-based proteomics services to Cancer Consortium (Consortium) members. The Proteomics resource's mission is to provide high quality service in a timely manner for small- and large-scale qualitative and quantitative proteomics analyses, protein modification characterization, and targeted proteomic analyses. These services have evolved from small-scale identification of protein complexes in model systems and identifying modifications on highly purified proteins to large-scale biomarker discovery/validation experiments in serum samples and phosphoproteomics analysis of animal organs. The PMSR received an outstanding merit assessment in 2008. In 2010, the PMSR was expanded to include metabolomics research and related resources through the joint recruitment of Daniel Raftery, Ph.D., a recognized leader in metabolomics research, to FHCRC and the University of Washington (UW). Along with the proteomics services mentioned above, the resource now provides untargeted profiling of aqueous metabolites and lipids (lipidomics), targeted profiling of metabolites from numerous metabolic pathways via mass spectrometry and nuclear magnetic resonance spectroscopy, and isotope tracer capabilities. The PMSR is also rapidly developing mass spectrometry phospholipid analysis. The resource is committed to developing and implementing new proteomics and metabolomics tools in order to uncover the molecular details that influence cancer biology and to support development of diagnostic and clinical tests. Scientific operations of the Proteomics and Metabolomics resource are divided between FHCRC and UW- medicine sites. Dr. Gafken oversees all operations at FHCRC and Dr. Raftery oversees those at UW. Drs. Gafken and Raftery meet on a monthly to coordinate activities, or more frequently if needed for specific projects. All proteomics-based projects are performed at FHCRC while metabolomics-based projects are divided between the two sites. Metabolomics projects for which established, routine assays are available are performed at FHCRC while those metabolomics projects that are non-routine and require significant development are performed at UW. As new metabolomics assays are developed and refined at the UW site, FHCRC-based staff will be trained on these protocols to make them more widely available as a service. All NMR capabilities and NMR-related projects will be conducted at UW-SLU.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-44
Application #
9617708
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Stromnes, Ingunn M; Hulbert, Ayaka; Pierce, Robert H et al. (2017) T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 5:978-991
Ladiges, Warren; Snyder, Jessica M; Wilkinson, Erby et al. (2017) A New Preclinical Paradigm for Testing Anti-Aging Therapeutics. J Gerontol A Biol Sci Med Sci 72:760-762
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Miller, Natalie J; Church, Candice D; Dong, Lichun et al. (2017) Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res 5:137-147
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020
Wang, Yu Winston; Reder, Nicholas P; Kang, Soyoung et al. (2017) Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy. Cancer Res 77:4506-4516
Miles, Fayth L; Navarro, Sandi L; Schwarz, Yvonne et al. (2017) Plasma metabolite abundances are associated with urinary enterolactone excretion in healthy participants on controlled diets. Food Funct 8:3209-3218
Hanron, Amelia E; Billman, Zachary P; Seilie, Annette M et al. (2017) Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs. Malar J 16:208
Ashenberg, Orr; Padmakumar, Jai; Doud, Michael B et al. (2017) Deep mutational scanning identifies sites in influenza nucleoprotein that affect viral inhibition by MxA. PLoS Pathog 13:e1006288
Paulson, Kelly G; Lewis, Christopher W; Redman, Mary W et al. (2017) Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer 123:1464-1474

Showing the most recent 10 out of 1144 publications